FAST NEWS: Viva Biotech completes Langhua Pharma buyout
The latest: Viva Biotech Holdings (1873.HK) announced Thursday that the acquisition of 20% of Langhua Pharmaceutical by its Weizongchen Pharmaceutical subsidiary for 640 million yuan ($87.6 million) has been completed. Looking…
Recent Articles
RELATED ARTICLES
-
GenScript losses shrink on strong growth for cancer cell therapy
1548.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
HBM gets health boost from drug licensing deals
2142.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Profit setback for Simcere Pharma in novel drugs quest
2096.HK
- Sichuan Biokin chases Hong Kong listing after BSM drug deal
-
AI drugs researcher QuantumPharm makes market debut on long road to profit
2228.HK
Discover hidden China stock gems in our weekly newsletter